Meeder Asset Management’s Cogent Biosciences COGT Stock Holding History

Meeder Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.39K	Buy	+140	New	+$5.17K	﹤0.01%	809
2019 Q4	–	Sell	-1,142	Closed	-$7K	–	2273
2019 Q3	$7K	Buy	1,142 +1,000	+704%	+$8.13K	﹤0.01%	1637
2019 Q2	$1K	Buy	142 +71	+100%	+$945	﹤0.01%	1936
2019 Q1	$1K	Sell	71 -99	-58%	-$1.69K	﹤0.01%	1612
2018 Q4	$2K	Buy	170 +131	+336%	+$3.88K	﹤0.01%	1563
2018 Q3	$2K	Buy	+39	New	+$2.2K	﹤0.01%	1431

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Meeder Asset Management's COGT Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Cogent Biosciences (COGT) in Q1 2026: 140 shares worth $5.39K. The stake represents ﹤0.01% of the portfolio and ranks #809 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in COGT as recently as Q3 2019.

Meeder Asset Management first reported a position in COGT in Q3 2018 and has held it in 6 quarters since. The position peaked at $7K in Q3 2019. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Meeder Asset Management held 140 shares of Cogent Biosciences worth $5.39K as of Q1 2026.
Cogent Biosciences was a new Meeder Asset Management position in Q1 2026.
Cogent Biosciences made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #809 holding.
Meeder Asset Management first reported a position in Cogent Biosciences in Q3 2018 and has held it in 6 quarters since.
Meeder Asset Management's Cogent Biosciences position peaked at $7K in Q3 2019.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.